Viking Therapeutics, Inc.
VKTXAPI behind this page
VKTX FY 2025 request
Playground key active
/api/financials?ticker=VKTX&year=2025&quarter=4&full_year_mode=true
Pick an endpoint and run the request.Income Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Research & Development | 344,955 | 101,644 | +239.4% |
| General & Administrative | 48,387 | 49,277 | -1.8% |
| Operating Expenses | 393,342 | 150,921 | +160.6% |
| Operating Income | -393,342 | -150,921 | -160.6% |
| Amortization Of Financing Costs Equity Transactions | -56 | -94 | +40.4% |
| Interest Income Expense Nonoperating Net | 33,704 | 40,940 | -17.7% |
| Realized Investment Gains Losses | 55 | 112 | -50.9% |
| Other Non-Operating Income (Expense) | 33,703 | 40,958 | -17.7% |
| Net Income | -359,639 | -109,963 | -227.1% |
Show Equity Components breakouts |
|||
| Retained Earnings | -359,639 | -109,963 | -227.1% |
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | 1,119 | -173 | +746.8% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 1,119 | -173 | +746.8% |
| Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax | 47 | -226 | +120.8% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 47 | -226 | +120.8% |
| Comprehensive Income | -358,473 | -110,362 | -224.8% |
| EPS (Basic) | -3.19 | -1.01 | -215.8% |
| Wtd Avg Shares (Basic) | 112,667 | 109,037 | +3.3% |
| EPS (Diluted) | -3.19 | -1.01 | -215.8% |
| Wtd Avg Shares (Diluted) | 112,667 | 109,037 | +3.3% |
| Income Before Taxes | -359,639 | -109,963 | -227.1% |
| Income Tax Expense (Benefit) | 1 | 1 | 0.0% |
Balance Sheet
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 165,810 | 26,676 | +521.6% |
| Available For Sale Securities Debt Securities Current | 539,929 | 875,936 | -38.4% |
| Prepaid Clinical Trial And Preclinical Study Costs | 8,053 | 3,476 | +131.7% |
| Prepaid Expenses & Other Current Assets | 1,806 | 1,128 | +60.1% |
| Total Current Assets | 715,598 | 907,216 | -21.1% |
| Non-Current Assets | |||
| Operating Lease Right-of-Use Assets | 85 | 1,003 | -91.5% |
| Deposits Assets Noncurrent | 46 | 46 | 0.0% |
| Total Assets | 715,729 | 908,321 | -21.2% |
| Current Liabilities | |||
| Accounts Payable | 53,251 | 9,813 | +442.7% |
| Other Accrued Liabilities Current | 23,279 | 17,111 | +36.0% |
| Operating Lease Liability Current | 137 | 489 | -72.0% |
| Total Current Liabilities | 76,667 | 27,413 | +179.7% |
| Non-Current Liabilities | |||
| Total Liabilities | 76,667 | 28,043 | +173.4% |
| Stockholders' Equity | |||
| Common Stock | 1 | 1 | 0.0% |
| Additional Paid In Capital Common Stock | 1,486,229 | 1,368,972 | +8.6% |
| Retained Earnings | -847,546 | -487,907 | -73.7% |
| Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | 378 | -788 | +148.0% |
| Total Stockholders' Equity | 639,062 | 880,278 | -27.4% |
| Total Liabilities & Equity | 715,729 | 908,321 | -21.2% |
Cash Flow Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Net Income | -359,639 | -109,963 | -227.1% |
| Accretion Amortization Of Discounts And Premiums Investments | -9,284 | -17,267 | +46.2% |
| Stock-Based Compensation | 40,818 | 29,712 | +37.4% |
Show Award Date breakouts |
|||
| January 2023 [Member] · Performance Based Restricted Stock Units [Member] | 1.8 | — | — |
| January 2024 [Member] · Performance Based Restricted Stock Units [Member] | 1.7 | — | — |
| January 2025 [Member] · Performance Based Restricted Stock Units [Member] | 9.2 | — | — |
Show Award Type breakouts |
|||
| Employee Stock Option | 15,279 | 11,017 | +38.7% |
| Employee Stock Purchase Plan [Member] | 752 | 1,094 | -31.3% |
| Performance Based Restricted Stock Units [Member] | 4.5 | — | — |
| Restricted stock and restricted stock units [Member] | 24,787 | 17,601 | +40.8% |
Show Income Statement Location breakouts |
|||
| General And Administrative Expense | 27,655 | 20,791 | +33.0% |
| Research And Development Expense | 13,163 | 8,921 | +47.6% |
| Operating Lease Right Of Use Asset Amortization Expense | 431 | 346 | +24.6% |
| Operating Leases Interest Expense | 10 | 38 | -73.7% |
| Change in Prepaid & Other Assets | -5,199 | 446 | -1265.7% |
| Change In Accrued Interest Relating To Marketable Securities Held As Investments | 5,076 | 1,199 | +323.4% |
| Change in Accounts Payable | 43,438 | 2,303 | +1786.1% |
| Increase Decrease In Accrued Liabilities | 6,168 | 5,816 | +6.1% |
| Increase Decrease In Operating Lease Liability | -505 | -402 | -25.6% |
| Net Cash from Operations | -278,685 | -87,790 | -217.4% |
| Investing Activities | |||
| Payments To Acquire Investments | -418,037 | -1,113,368 | +62.5% |
| Proceeds From Sale Maturity And Collections Of Investments | 759,425 | 560,002 | +35.6% |
| Net Cash from Investing | 341,388 | -553,366 | +161.7% |
| Unpaid Deferred Initial Public Offering And Other Financing Costs | 50 | 50 | 0.0% |
| Financing Activities | |||
| Proceeds From Warrant And Option Exercises And Stock Issuance Under Employee Stock Purchase Plan | 2,491 | 10,813 | -77.0% |
| Proceeds From Issuance Of At The Market Equity Offering Sales Agreement Net Of Fees | 73,948 | 46,658 | +58.5% |
| Net Cash from Financing | 76,439 | 612,464 | -87.5% |
| Other Cash Flow | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | 139,142 | -28,692 | +585.0% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 165,810 | 26,676 | +521.6% |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | -8 | -148 | +94.6% |
Values in thousands USD. Source: SEC EDGAR 10-K filing.